Interestingly, rosiglitazone reduced the levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in patients with acromegaly and promoted apoptosis and autophagy in primary somatotroph adenoma and GH3 cells (Zhang et al., 2021). Here, GH1 is linked to acromegaly.